Nitrogen-Containing Cyclic Compounds for Bone Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone fractures, especially those associated with osteoporosis, face challenges such as prolonged healing times, malunion, delayed union, and nonunion, leading to significant complications and increased healthcare costs, with existing medications like PGE2 having side effects that limit their long-term use.
Innovation Solution
Development of novel nitrogen-containing 6-membered cyclic compounds with superior EP4 receptor agonist activity, which can be used as active ingredients in medicaments to promote osteogenesis and fracture healing, offering a safer and more effective alternative to existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PGE2 is used to promote osteogenesis and bone healing, then bone healing is promoted, but side effects occur that limit long-term use
Solution Approach 1:
The patent modifies the chemical structure of PGE2 by changing parameters such as introducing nitrogen-containing 6-membered cyclic compounds with specific substituents (R1, Ar1, Ar2 groups) to create EP4 receptor-selective agonists that maintain bone healing effects while reducing harmful side effects through structural parameter optimization
Solution Approach 2:
The invention achieves local quality by creating compounds with specific molecular structures (formula 1) that selectively activate EP4 receptors in bone tissues while avoiding activation of other receptors that cause side effects, thereby achieving localized beneficial effect without systemic harm
2Reliability
If existing fracture treatments are used, then fracture healing is achieved, but healing time is prolonged and complications occur
Solution Approach 1:
The patent changes the pharmacological parameters of fracture treatment by introducing novel nitrogen-containing cyclic compounds with optimized molecular structures that enhance EP4 receptor agonist activity, thereby accelerating fracture healing while reducing complications such as malunion and nonunion
3Reliability
If daily activities are restrained during fracture treatment, then fracture healing is protected, but muscle atrophy and bone mass reduction occur
Solution Approach 1:
The patent introduces EP4 receptor-selective agonist compounds as an intermediary substance that enables bone healing promotion without requiring complete restriction of daily activities, thereby preventing muscle atrophy and bone mass reduction while still protecting fracture healing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate enhanced EP4 receptor agonist activity, facilitating therapeutic treatment and promotion of bone healing, reducing the risk of complications associated with osteoporotic fractures and improving patient quality of life.
Implementation Method 1
the compounds of the present invention have a superior EP4 receptor agonist activity
Data Source
AI summary
A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.